|
|
|
|
Communication breakdown: what happens to nerve cells in Parkinson's disease
A new study from The Montreal Neurological Institute and Hospital The Neuro - at McGill University is the first to discover a molecular link between Parkinson's disease and defects in the ability of nerve cells to communicate.The study, published in...
|
|
|
Parkinson's Linked to Industrial Cleaner
(Ivanhoe Newswire) -- Workers exposed to tricholorethylene (TCE), a chemical once widely used to clean metal such as auto parts, may be at significant risk of developing Parkinson's disease."This is the first time a population-based study has confirmed...
|
|
|
Industrial Cleaner Linked To Increased Risk Of Parkinson's Disease
Industrial Cleaner Linked To Increased Risk Of Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites Compare and save on surgery Medical and Clinical Translation Details of over 40,000 UK Specialists and over 42,000 GPs medical software...
|
|
|
Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Dis
- Targacept, Inc.(NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from (MJFF). The grant is to fund a project entitled: Development of an alpha6*...
|
|
|
Parkinson's Disease Risk Increases With Use of Industrial Cleaner
A study released today says that workers exposed to tricholorethylene (TCE), a chemical once widely used to clean metal such as auto parts, may be at a significantly higher risk of developing Parkinson's disease.The study will be presented at the...
|
|
|
Cleaning Agent Tied to Parkinson's in Study
MONDAY, Feb.8 (HealthDay News) -- The industrial cleaner trichloroethylene (TCE) has been linked to an increased risk of Parkinson's disease, U.S. researchers say. 'TCE was once a popular industrial solvent used in dry cleaning and to clean grease...
|
|
|
Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinsons disease biomarker
Targacept, Inc.(NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The...
|
|
|
Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinsons Disease
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc.(NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from (MJFF). The grant is to fund a project...
|
|
|
Geisinger Hospitals Offer Unique Treatment For Movement Disorders
Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.Parkinson's disease and other movement disorders can...
|
|
|
New revolutionary treatment for patients suffering from movement disorders
Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.Parkinson's disease and other movement disorders can...
|
|
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
PALO ALTO, CA, Feb 8 --(HSMN NewsFeed)-- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases,...
|
|
|
Reportlinker Adds What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 201
NEW YORK, Feb.9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many...
|
|
|
AMT To Present at the BIO CEO & Investors Conference ' 9th February 2010
CNS Diseases Breaking News News source: Business Wire AMT is a leader in the field of gene therapy.Its first product is in registration in EU for Lipoprotein Lipase Deficiency, an orphan condition. AMT's other development programmes include: Hemophilia, ...
|
|
|
XenoPort Announces Extension of the Horizant(TM) PDUFA Date to February 11, 2010
(BUSINESS WIRE) ----XenoPort, Inc.(Nasdaq:XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the Horizant (gabapentin enacarbil) new drug application (NDA) for moderate-to-severe primary Restless...
|
|
|
XenoPort Announces Extension of the Horizant(TM) PDUFA Date to February 11, 2010
(BUSINESS WIRE) ----XenoPort, Inc.(Nasdaq:XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the Horizant (gabapentin enacarbil) new drug application (NDA) for moderate-to-severe primary Restless...
|
|
|
Anticholinergic activity and cognitive decline in Parkinson's disease
_ Anticholinergic activity and cognitive decline in Parkinson's disease.
Journal of Neurology, Neurosurgery & Psychiatry:
Feb 9 2010 10:31PM
Matching: parkinson
|
Find similar documents
|
|
|
|
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study
_ Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study.
Journal of Neurology, Neurosurgery & Psychiatry:
Feb 9 2010 10:30PM
Matching: parkinson
|
Find similar documents
|
|
|
|
Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders?
_ Comparative analysis of gait and speech in Parkinson's disease: hypokinetic or dysrhythmic disorders?.
Journal of Neurology, Neurosurgery & Psychiatry:
Feb 9 2010 10:30PM
Matching: parkinson
|
Find similar documents
|
|
|
|
Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studi
_ Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studi.
Journal of Neurology, Neurosurgery & Psychiatry:
Feb 9 2010 10:29PM
Matching: parkinson
|
Find similar documents
|
|
|
|
XenoPort Announces Extension of the Horizant(TM) PDUFA Date to Fe...
Company: Xenoport Inc (XNPT) XenoPort, Inc.(Nasdaq:XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the Horizant (gabapentin enacarbil) new drug application (NDA) for moderate-to-severe primary...
|
|
|
Drinking milk during pregnancy may lower baby's risk of MS
PAUL, Minn.Drinking milk during pregnancy may help reduce your baby's chances of developing multiple sclerosis (MS) as an adult, according to a preliminary study released today that will be presented at the 's 62nd Annual Meeting in Toronto April 10 to April...
|
|
|
XenoPort Announces Extension of the Horizant(TM) PDUFA Date to February 11, 2010
SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc.(Nasdaq: XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the Horizant (gabapentin enacarbil) new drug application (NDA) for moderate-to-severe...
|
|
|
XenoPort Announces Extension of the Horizant PDUFA Date to February 11, 2010
XenoPort, Inc.(Nasdaq:XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the Horizant (gabapentin enacarbil) new drug application (NDA) for moderate-to-severe primary Restless Legs Syndrome (RLS),...
|
|
|
XenoPort Announces Extension of the Horizant(TM) PDUFA Date to February 11, 2010
XenoPort, Inc.(NASDAQ:XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the Horizant (gabapentin enacarbil) new drug application (NDA) for moderate-to-severe primary Restless Legs Syndrome (RLS),...
|
|
|
XenoPort Announces Extension of the Horizant PDUFA Date to February 11, 2010
XenoPort Announces Extension of the Horizant PDUFA Date to February 11, 2010 SANTA CLARA, Calif.- (BUSINESS WIRE) - XenoPort, Inc. (Nasdaq:XNPT) announced today that the U.S. Food and Drug Administration (FDA) will not be taking an action today on the...
|
